Quanterix Corp (NASDAQ:QTRX) Director John M. Connolly bought 2,700 shares of Quanterix stock in a transaction on Tuesday, December 4th. The shares were purchased at an average cost of $18.38 per share, for a total transaction of $49,626.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
QTRX stock traded up $0.31 during trading on Friday, reaching $19.50. 106,483 shares of the stock were exchanged, compared to its average volume of 69,304. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.11 and a quick ratio of 3.76. Quanterix Corp has a 1 year low of $13.00 and a 1 year high of $24.81. The company has a market capitalization of $425.98 million and a PE ratio of -2.35.
Quanterix (NASDAQ:QTRX) last issued its earnings results on Wednesday, November 7th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.07). Quanterix had a negative return on equity of 52.35% and a negative net margin of 88.72%. The firm had revenue of $10.59 million for the quarter, compared to analysts’ expectations of $9.57 million. Sell-side analysts forecast that Quanterix Corp will post -1.21 EPS for the current year.
Hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC purchased a new position in Quanterix during the second quarter worth about $117,000. Teachers Advisors LLC purchased a new position in Quanterix during the third quarter worth about $219,000. Granite Investment Partners LLC purchased a new position in Quanterix during the third quarter worth about $346,000. First Republic Investment Management Inc. purchased a new position in Quanterix during the second quarter worth about $235,000. Finally, PNC Financial Services Group Inc. purchased a new position in Quanterix during the third quarter worth about $428,000. 49.62% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by BBNS and is owned by of BBNS. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://baseballnewssource.com/2018/12/08/quanterix-corp-qtrx-director-john-m-connolly-buys-2700-shares-of-stock/3065148.html.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer.
Further Reading: What is the Rule of 72?
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.